NCT04111172View on ClinicalTrials.gov

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Pancreatic Ductal AdenocarcinomaColorectal AdenocarcinomaGastric AdenocarcinomaClinical Stage II Gastric Cancer AJCC v8Clinical Stage IIA Gastric Cancer AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Gastric Cancer AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Malignant Solid NeoplasmPathologic Stage II Gastric Cancer AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastric Cancer AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Gastric Cancer AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastric Cancer AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Stage I Pancreatic Cancer AJCC v8Stage IA Pancreatic Cancer AJCC v8Stage IB Pancreatic Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Malignant Digestive System NeoplasmSmall Intestinal AdenocarcinomaStage III Small Intestinal Adenocarcinoma AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Interventions
BIOLOGICAL

Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE

Given as intramuscular injection

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER